This story is very close to my heart.  Not only is Don Wright a close friend, but former NFL football player, Elijah Alexander, and I became friends before he died a a year or so ago.

While we were busy being inspired–and reading nutritional tips to help us control our myeloma–there was a lot going on with the new myeloma therapies and the FDA.

OncologySTAT ran this feature article about pomalidomide last week in their hematology edition.  Here are a few excerpts:

Let’s do some housecleaning and catch-up on some myeloma related news and views:

Medscape Today has released an excellent written and video review of multiple myeloma-related news from ASH.

If your read Friday’s post about my emotional evening at the IMF’s International Jounalist event last week, you will probably recall how my roller-coaster “crashed down” after hearing about an unexpectedly short, 8 month overall survival (OS) benefit from using pomalidomid and dexamethasone after patients became refractory to Revlimid and Velcade.

I know, I know.  I’m falling behind!  I’m so busy collecting and analyzing newly released myeloma related research data, I have barely had time to write.

I just posted a press release from Celgene, announcing their 3rd quarter financials for 2011 on my MyelomaNews.com site.

Yesterday I wrote about how fortunate I was to have received second opinions–via email–from two well know, well respected mutliple myeloma experts.

The International Myeloma Foundation (IMF) reports that pomalidomide and carfilzomib “are both moving closer to approval for patients who have relapsed or do not respond to current drugs.” in their summer addition of Myeloma Today.

The Myeloma Beacon ran an excellent review of new anti-myeloma therapies which are in late stages of development: 

Wednesday I shared a few specifics from Celgene Corporation’s 2010 annual report.  You can read the company’s entire press release by going to Myeloma News.com and clicking on:
CELGENE REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2010 OPERATING AND FINANCIAL RESULTS.

Here is an interesting article I found in the Cornell Daily Sun this morning.  Interesting because it is combines basics with a very insightful look at a promising clinical trial featuring pomalidomide:

Here is a link to a comprehensive analysis of stem cell transplant results (SCT) from the Journal of Clinical Oncology:  Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols.

I just reported some positive news about Revlimid on Sunday, American Society of Clinical Oncology Recognizes Revlimid As One Of The Year’s “Most Notable Advances.” 

Saturday I started sharing some basics for newly diagnosed multiple myeloma patients and caregivers, Tips To Raise Your Multiple Myeloma IQ.

It is always interesting to see how each multiple myeloma related publication or organization views news coming out of a large conference like ASH.

Good morning!  I have neglected reporting about pomalidomide.  This new, experimental, novel therapy agent continues to impress in a slow, deliberate way.

This is very good news as posted on OncologySTAT yesterday:

Yesterday I shared Dr. Stewart’s hopeful message to patients for whom
Revlimid and Velcade no longer work.  Here is his response to the question:
Should I consider a clinical trial? What new therapies in clinical trials look promising? 
as posted on the Multiple Myeloma Research Foundation (MMRF) site recently: